Its half-life is approximately 5 days, allowing for once-a-week subcutaneous injection
In pregnant female rats given subcutaneous doses of 0.1, 0.25 and 1 mg/kg/day liraglutide from gestation day 6 through weaning or termination of nursing on lactation day 24, estimated systemic exposures were 0.8-, 3-, and 11-times exposure in obese humans at the MRHD of 3 mg/day, based on plasma AUC comparison
Marlatt KL, Lovre D, Beyl RA, et al
Unlike unregulated, research-grade peptides sourced from overseas, this is a physician-guided therapy designed for safety, accuracy, and real outcomes
BPC-157 is available through medical providers who work with licensed 503A compounding pharmacies